ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity

Journal of Biomedical Research

Volumn 25, Issue 4, 2011, Pages 266-273

  Lu, Min ^a   Lu, Qun ^a   Zhang, Yong ^a   Tian, Gang ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

ApoB apoA1 ratio; Coronary heart disease; Obesity; Overweight

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PREDICTION; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80052304175     PISSN: 16748301     EISSN: 16748301     Source Type: Journal    
DOI: 10.1016/S1674-8301(11)60036-5     Document Type: Article

References (31)

1. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. New Engl J Medi 2005, 352:29-38.
2. Sharma RK, Singh VN, Reddy HK Thinking beyond lowdensity lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vasc Health Risk Manag 2009, 5:793-799.
3. Rana JS, Boekholdt SM Should we change our lipid management strategies to focus on non-high-density lipoprotein cholesterol?. Curr Opinion in Cardiol 2010, 25:622-626.
4. Faergeman O Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease. J Intern Med 2006, 259:434-436.
5. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006, 259:247-258.
6. Walldius G, Jungner I Apolipoprotein B and apolipo-protein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004, 255:188-205.
7. Cromwell WC, Barringer TA Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. Curr Cardiol Rep 2009, 11:468-475.
8. Florvall G, Basu S, Larsson A Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol A Biol Sci Med Sci 2006, 61:1262-1266.
9. Ajees AA, Anantharamaiah GM, Mishra VK, Hussain MM, Murthy HM Crystal structure of human apoli-poprotein A-I: insights into its protective effect against cardiovascular diseases. Proc Natl Acad Sci U S A 2006, 103:2126-2131.
10. Van Linthout S, Spillmann F, Riad A, Trimpert C, Lievens J, Meloni M, et al. Human apolipoprotein A-I gene transfer reduces the development of experimental diabetic cardiomyopathy. Circulation 2008, 117:1563-1573.
11. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O'Brien R, et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic proper-ties. Diabetologia 2007, 50:1770-1779.
12. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, et al. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multiethnic US population. Eur Heart J 2009, 30:710-717.
13. Superko HR, Gadesam RR Is It LDL Particle Size or Number that Correlates with Risk for Cardiovascular Disease?. Curr Atheroscler Rep 2008, 10:377-385.
14. Parish S, Peto R, Palmer A, Clarke R, Lewington S, Of-fer A, et al. The joint effects of apolipoprotein B, apolipoprotein A(1), LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls. Eur Heart J 2009, 30:2137-2146.
15. Thompson A, Danesh J Associations between apolipo-protein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006, 259:481-492.
16. Thomas T, Ginsberg H Targeting ApoB as a therapeutic approach for the treatment of dyslipidemia: the potential role of mipomersen. Clin Lipidol 2010, 5:457-464.
17. Walldius G, Jungner I Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I - New risk factors and targets for therapy. Nutr Metab Cardiovas 2007, 17:565-571.
18. Superko HR, Gadesam RR Is it LDL particle size or number that correlates with risk for cardiovascular dis-ease?. Curr Atheroscler Rep 2008, 10:377-385.
19. Patel S, Di Bartolo BA, Nakhla S, Heather AK, Mitchell TW, Jessup W, et al. Anti-inflammatory effects of apol-ipoprotein A-I in the rabbit. Atherosclerosis 212:392-7.
20. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
21. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Atherosclerosis 2010, 213:299-305.
22. Arsenault BJ, Rana JS, Lemieux I, Despres JP, Kastelein JJ, Boekholdt SM, et al. Physical inactivity, abdominal obesity and risk of coronary heart disease in apparently healthy men and women. Int J Obes (Lond) 2010, 34:340-347.
23. Hlatky MA, Chung SC, Escobedo J, Hillegass WB, Melsop K, Rogers W, et al. The effect of obesity on quality of life in patients with diabetes and coronary artery disease. Am Heart J 2010, 159:292-300.
24. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian simvastatin survival study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93:136-141.
25. Saito I, Iso H, Kokubo Y, Inoue M, Tsugane S Meta-bolic syndrome and allcause and cardiovascular disease mortality: Japan Public Health Center-based Prospective (JPHC) Study. Circ J 2009, 73:878-884.
26. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006, 26:968-976.
27. Rana JS, Nieuwdorp M, Jukema JW, Kastelein JJP Car-diovascular metabolic syndrome - an interplay of, obes-ity, inflammation, diabetes and coronary heart disease. Diabetes Obes Metab 2007, 9:218-232.
28. Tsai J, Zhang RN, Qiu W, Su QZ, Naples M, Adeli K Inflammatory NF-kappa B activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production. Am J Physiol-Gastr Liver Physiol 2009, 296:G1287-G1298.
29. Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, di Minno G, Margaglione M, et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004, 53:852-857.
30. Halle M, Korsten-Reck U, Wolfarth B, Berg A Low-grade systemic inflammation in overweight children: impact of physical fitness. Exerc Immunol Rev 2004, 10:66-74.
31. Hastie CE, Padmanabhan S, Slack R, Pell ACH, Old-royd KG, Flapan AD, et al. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J 2010, 31:222-226.